Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.
about
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin DrugsEnhancing the Protective Immune Response against BotulismAntibodies for biodefenseProduction and characterisation of a neutralising chimeric antibody against botulinum neurotoxin AEnhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion proteinMechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.Molecular assembly of botulinum neurotoxin progenitor complexes.Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque originEpitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain).Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.RBC Adherence of Immune Complexes Containing Botulinum Toxin Improves Neutralization and Macrophage Uptake.A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.What next for botulism vaccine development?Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.Antibodies against anthrax: mechanisms of action and clinical applications.Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain.Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic ActivityDevelopment of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BIsolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.Monoclonal antibodies and toxins--a perspective on function and isotype.Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and BDNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and EDevelopment of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E.Challenges in searching for therapeutics against Botulinum Neurotoxins.The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.
P2860
Q26863621-F81334DF-3258-4776-ADB5-785344E1C981Q27678122-DD15A4B6-620E-444F-9CC5-5433DD91E6CDQ28394941-93EA91FD-0D85-498F-BC3B-0DD8367825FAQ28475753-C9F33B74-A3BF-4B25-9BDF-F3CE72FF1625Q28742292-37A0711C-2F23-4E7B-A653-719C4CD69269Q30408386-5FFB519F-3427-4038-914F-A5DFC7A6509FQ30538466-62232D85-6B6F-4F79-9559-51D72F730F61Q31042202-2079906B-99C4-457A-BC84-52B56DF2EE3FQ33418600-5C67E9D6-9680-496C-B4BE-113176A45241Q33526251-0454C1A2-10B1-4CC8-AC79-9DBDD882E90EQ33613925-4D48D213-859C-4211-9ACE-00E35807C45AQ33744802-2AC5BFF0-5529-4BCA-AEB3-0EC26F2FA864Q34125366-1646AEF1-A54F-4C8A-B940-F22E15BC6456Q34343808-9D1EE935-3B80-442D-8DBF-DAA7DE59F065Q35542237-9EE4400B-4908-489D-A497-521099CEFB36Q35610439-5712322B-8F1E-450E-B8AD-D564647C5E0FQ35699428-D281F201-3CAD-41AF-A682-82DBDA0751ABQ35746555-84BB9275-4BD5-48D7-9F1E-2255BE62D91AQ35779652-123DD1C7-DB48-4C3B-8304-119C2FBACEF8Q35780060-96EB5F88-877E-45D4-9D11-5ECC8D036538Q36099489-AE3D3B3D-964B-4A1B-9C00-F8FB8BD8E592Q36112959-2BD73788-83D8-438B-A7A8-33DB4AE9E8E7Q37530489-CC23AE1D-185A-4BA5-8151-4C0EB664E2C3Q37698936-FEE2D89B-94D7-4B3E-9DFF-5492B72CA0E2Q38696776-DFED124B-DBE6-43DC-8C3C-2E18039E36F2Q39167871-01922F81-B4F5-4104-B127-3EBE3B4D76E3Q45235847-795098F1-FE3A-4D7B-97DF-7C314EC6B969Q49805666-BB00D238-5665-4A5E-8C4F-EB24A1E77B2BQ52679598-16AD8171-03E9-4A2B-8125-B0ADDC42F63A
P2860
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Neutralization of botulinum ne ...... for the catalytic light chain.
@ast
Neutralization of botulinum ne ...... for the catalytic light chain.
@en
type
label
Neutralization of botulinum ne ...... for the catalytic light chain.
@ast
Neutralization of botulinum ne ...... for the catalytic light chain.
@en
prefLabel
Neutralization of botulinum ne ...... for the catalytic light chain.
@ast
Neutralization of botulinum ne ...... for the catalytic light chain.
@en
P2093
P2860
P1433
P1476
Neutralization of botulinum ne ...... for the catalytic light chain.
@en
P2093
B P Kapadnis
Denise M Ancharski
Fetweh H Al-Saleem
Lance L Simpson
Michael J Root
R Mark Jones
Scott K Dessain
Sharad P Adekar
Tsuyoshi Takahashi
P2860
P356
10.1371/JOURNAL.PONE.0003023
P407
P577
2008-08-20T00:00:00Z